-+ 0.00%
-+ 0.00%
-+ 0.00%

Celldex Therapeutics Q3 EPS $(1.01) Misses $(0.91) Estimate

Benzinga·11/10/2025 21:46:21
Listen to the news
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.91) by 10.87 percent. This is a 57.81 percent decrease over losses of $(0.64) per share from the same period last year.